Provided by Tiger Trade Technology Pte. Ltd.

Pfizer

27.64
+0.18000.66%
Post-market: 27.660.0200+0.07%16:17 EDT
Volume:28.44M
Turnover:786.59M
Market Cap:157.15B
PE:36.37
High:27.81
Open:27.62
Low:27.55
Close:27.46
52wk High:29.21
52wk Low:23.58
Shares:5.69B
Float Shares:5.64B
Volume Ratio:0.95
T/O Rate:0.50%
Dividend:1.72
Dividend Rate:6.22%
EPS(TTM):0.7599
EPS(LYR):1.36
ROE:5.01%
ROA:5.78%
PB:1.84
PE(LYR):20.26

Loading ...

Pfizer's Mixed Q2 Results: Oncology Gains Offset COVID Revenue Declines

Deep News
·
Aug 04

Pfizer Stock (PFE) Flat on 2026 Sales Outlook as Cancer Drugs Fuel Q2 Beat

TIPRANKS
·
Aug 04

Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis

Bloomberg
·
Aug 04

Pfizer: in 2026, NOW Expect Unfavorable Revenue Impact from Patent-Based or Regulatory Exclusivity Expiries of Approximately $1.1 Bln- SEC Filing

THOMSON REUTERS
·
Aug 04

Pfizer Logs Mixed 2Q on Oncology Growth, Covid-19 Declines

Dow Jones
·
Aug 04

Why Pfizer Stock and This Covid Vaccine Partner are Falling on Earnings

Dow Jones
·
Aug 04

Pfizer Q2 Adjusted Earnings Decline, Revenue Increases; 2026 Revenue Outlook Narrowed

MT Newswires Live
·
Aug 04

Pfizer reports Q2 adjusted EPS 77c, consensus 68c

TIPRANKS
·
Aug 04

Pfizer backs FY26 adjusted EPS view $2.80-$3.00, consensus $2.95

TIPRANKS
·
Aug 04

Pfizer announces expansion of productivity enhancement Initiatives

TIPRANKS
·
Aug 04

Pfizer Beats Earnings Estimates, Targets $2.5 Billion in Additional Cost Cuts

Reuters
·
Aug 04

Pfizer Says Q2 2026 Results Beat Expectations on Non-COVID Brand Growth and Cost Discipline

Reuters
·
Aug 04

Pfizer- Plan to Advance Phase 3 Program for Berobenatide That Includes 10 Studies for Chronic Weight Management, Obesity-Related Conditions This Year

THOMSON REUTERS
·
Aug 04

Pfizer - Aim Delivering Risk-Adjusted High Single-Digit Revenue Cagr from Year-End 2028 Through Year-End 2033- Prepared Remarks

THOMSON REUTERS
·
Aug 04

Pfizer: Expect a Pivotal Trial Start This Year Investigating Nurtec’s Use as a Treatment for Chronic Migraine- Prepared Remarks

THOMSON REUTERS
·
Aug 04

Pfizer - Targeting First Berobenatide Approval in 2028 - Prepared Remarks

THOMSON REUTERS
·
Aug 04

Pfizer - Powered in Part by Rapid Advancement of Technology, Net Cost Savings from NOW Expected to Total $6.7 Bln Through 2029 - Prepared Remarks

THOMSON REUTERS
·
Aug 04

Pfizer - We NOW Expect an Additional $1 Billion in Savings from Our Ongoing Cost Realignment Program- Prepared Remarks

THOMSON REUTERS
·
Aug 04

Pfizer: Already Seeing Benefits from AI in Reducing Costs & Expanding Yields in Manufacturing- Prepared Remarks

THOMSON REUTERS
·
Aug 04

Pfizer: Expect Post-2028 Cash Flow to Benefit from Previously Announced Vyndamax Patent Settlement

THOMSON REUTERS
·
Aug 04